Wyeth Ends Temsirolimus Breast Cancer Trial
This article was originally published in The Pink Sheet Daily
The firm cites inadequate efficacy results from an interim analysis of a Phase III breast cancer trial; other oncology trials for temsirolimus are ongoing.
You may also be interested in...
CCI-779 (temsirolimus) monotherapy is associated with a 49% improvement in median overall survival compared to interferon in advanced renal cell carcinoma patients.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.